ANTIOXIDANT POTENTIAL OF SELECTED 1, 3, 4-OXADIAZOLE–BENZOTHIAZOLE DERIVATIVES: AN IN-VITRO STUDY

Oxidative stress results from an imbalance between the generation of reactive oxygen species and the body’s antioxidant defense mechanisms, leading to cellular damage. Antioxidants play a vital role in neutralizing free radicals and preventing oxidative injury. The present study was undertaken to evaluate the in-vitro antioxidant activity of synthesized 1, 3, 4-oxadiazole–benzothiazole derivatives using the Oyaizu reducing power method. Compound C3 and Compound V3 [2-(5′-substituted phenyl)-1′,3′,4′-oxadiazol-2′-yl amino)-6-fluoro-7-substituted (1,3)-benzothiazole derivatives], were assessed for their reducing ability by measuring the conversion of ferric ions (Fe³⁺) to ferrous ions (Fe²⁺) at 700 nm. Ascorbic acid was used as the standard antioxidant. Both compounds exhibited concentration-dependent antioxidant activity in the range of 20–120 µg/mL. Compound V3 showed a 34.65% increase in reducing power, while compound C3 showed a 32.33% increase at 120 µg/mL concentration. The results indicate that the synthesized 1, 3, 4-oxadiazole–benzothiazole derivatives may have antioxidant qualities based on their observed reducing potential. However, further research is needed to validate their biological relevance, including in-vivo studies, acute toxicity assessments, and other antioxidant assays such as DPPH, ABTS, or ORAC.